Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thebacon is a semisynthetic opioid analgesic and antitussive of the morphinan class, structurally related to hydrocodone and codeine. It acts primarily as an opioid receptor agonist, exerting its effects mainly through conversion in the liver to more potent opioids such as hydromorphone via CYP2D6 metabolism. Thebacon has slightly higher potency than hydrocodone and is approximately eight times stronger than codeine by weight. It was formerly used in Europe under brand names like Acedicon for pain relief and cough suppression but is now rarely used clinically. In the United States, it is classified as a Schedule I controlled substance due to its high abuse potential and lack of accepted medical use[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thebacon.